Brazil Pharma Announces Material Fact

São Paulo, May 08, 2012 - Brazil Pharma S.A. (Brazil Pharma) - (BM&FBovespa: BPHA3), a capital authorized publicly-held company, whose common shares are traded on the BM&FBOVESPA - Securities, Commodities and Futures Exchange ("BM&FBOVESPA") under the ticker "BPHA3" ("Company"), in accordance with CVM Rule 358 of January 3, 2002, as amended, and CVM Rule 471 of August 8, 2008 ("CVM Rule 471"), hereby informs its shareholders and the market in general the following:

Today, the Company and the individual selling shareholders identified in the offering memorandum ("Selling Shareholders") submitted to ANBIMA - Brazilian Association of Financial and Capital Market Entities ("ANBIMA") a request for previous analysis of registration of primary and secondary public offering of no-par, registered book entry common shares issued by the Company, free and clear of all encumbrances ("Offering" and "Shares", respectively). This request for previous analysis of registration of the Offering is based on the simplified procedures set forth in CVM Rule 471 and ANBIMA's Code of Regulation and Best Practices.

The Offering will comprise the primary and secondary public offering of Shares in Brazil, on nonorganized over-the-counter market, pursuant to CVM Rule 400 of December 29, 2003, as amended ("CVM Rule 400"), including efforts for placement of Shares abroad for qualified institutional investors, resident and domiciled in the United States, defined as per Rule 144A of Securities Act of 1933, in operations exempted from registration provided for in the Securities Act, as well as for investors from countries other than United States and Brazil, not residing in the United States or companies not incorporated under the laws thereof.

distributed by